A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy

This study is testing a targeted-release form of budesonide — a steroid that acts directly in the gut — as an early treatment for IgA nephropathy, a kidney disease caused by a faulty immune protein building up in the kidneys. The goal is to see if starting this drug early can better protect kidney function. **You may be eligible if...** - You are 18–75 years old - You were recently diagnosed with primary IgA nephropathy confirmed by kidney biopsy (within the last 3 months) - Your kidneys still have reasonable function (eGFR ≥30) - You have significant protein leaking into your urine **You may NOT be eligible if...** - You have secondary IgA nephropathy (caused by another disease like liver disease or lupus) - You are already taking or have recently taken certain steroids or immunosuppressants - You have severe kidney damage or other major organ problems - You are pregnant or breastfeeding - You are allergic to budesonide Talk to your doctor to see if this trial is right for you.